Overview Performance Dividends Fundamentals Peer Group Correlations Pair Trades Institutions Insider Forecasts Options

NOV - Novo Nordisk A/S - Stock Price & Dividends

Exchange: XETRA Stock Exchange • Country: Denmark • Currency: EUR • Type: Common Stock • ISIN: DK0062498333

Insulin, Diabetes, Obesity, Hormone, Growth Hormone

Novo Nordisk A/S is a global pharmaceutical company that engages in the research, development, manufacture, and distribution of pharmaceutical products in various regions, including Europe, the Middle East, Africa, Asia, and North America.

The company operates through two main segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment provides a range of products for the treatment of diabetes, obesity, cardiovascular disease, and other emerging therapy areas. This segment is focused on developing innovative solutions to help people with diabetes and obesity manage their conditions and improve their quality of life.

The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. This segment is dedicated to developing treatments for rare and complex diseases that affect a small number of people worldwide.

In addition to its pharmaceutical products, Novo Nordisk A/S also provides a range of devices and solutions to help people with diabetes manage their condition. These include insulin pens, growth hormone pens, and injection needles. The company also offers smart solutions, such as smart insulin pens and the Dose Check application, which helps people with diabetes track their insulin doses and manage their treatment.

Novo Nordisk A/S has a strong commitment to innovation and collaboration. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products, and it also partners with other companies and organizations to develop new treatments and solutions for people with diabetes and rare diseases.

Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. The company has a long history of innovation and has developed many groundbreaking treatments for diabetes and other diseases. Today, Novo Nordisk A/S is one of the leading pharmaceutical companies in the world, and it continues to be a leader in the development of innovative treatments and solutions for people with diabetes and rare diseases.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for NOV - Novo Nordisk A/S - Stock Price & Dividends

NOV Stock Overview

Market Cap in USD 610,094m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception

NOV Stock Ratings

Growth 5y 98.6
Fundamental 2.93
Dividend 69.3
Rel. Performance vs Sector 0.80
Analysts -
Fair Price Momentum 167.56 EUR
Fair Price DCF 314.89 EUR

NOV Dividends

Dividend Yield 12m 1.12%
Yield on Cost 5y 10.65%
Dividends CAGR 5y 11.67%
Payout Consistency 95.0%

NOV Growth Ratios

Growth 12m 41.24%
Growth Correlation 12m 92%
Growth Correlation 3m -60%
CAGR 5y 55.86%
CAGR/Mean DD 5y 13.40
Sharpe Ratio 12m 1.14
Alpha vs SP500 12m 23.49
Beta vs SP500 5y weekly 0.71
ValueRay RSI 16.23
Volatility GJR Garch 1y 32.02%
Price / SMA 50 -1.82%
Price / SMA 200 7.79%
Current Volume 27.5k
Average Volume 20d 37.8k

External Links for NOV Stock

Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
What is the price of NOV stocks?
As of September 08, 2024, the stock is trading at EUR 118.48 with a total of 27,544 shares traded.
Over the past week, the price has changed by -5.47%, over one month by +3.24%, over three months by -6.88% and over the past year by +43.33%.
What are the forecast for NOV stock price target?
According to ValueRays Forecast Model, NOV Novo Nordisk A/S will be worth about 184.2 in September 2025. The stock is currently trading at 118.48. This means that the stock has a potential upside of +55.49%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 184.2 55.5

The Story of Novo Nordisk A/S

History

Novo Nordisk A/S, with its rich history that begins in early 20th century Denmark, stands today as a beacon in the healthcare industry, particularly in diabetes care. Founded from the merger of two small Danish companies, it has grown over the decades into a global leader in this vital field of medicine. Its journey from producing the first insulin in Scandinavia to innovating diabetes care solutions reflects its deep-rooted commitment to improving patient outcomes.

Core Business

At its core, Novo Nordisk is dedicated to defeating diabetes. Its portfolio heavily emphasizes insulin and other diabetes treatments, including modern insulins and oral antidiabetic drugs. This focus is driven by a mission to discover and develop innovative medicines to help people with diabetes lead longer, healthier lives. Beyond insulin, Novo Nordisk has also ventured into treatments for obesity, another critical healthcare area, further showing its commitment to confronting global health challenges.

Side Businesses

While Novo Nordisk’s primary focus remains on diabetes care, the company also operates in other areas of the healthcare sector. These include hemophilia care, growth hormone therapy, and hormone replacement therapies, extending its expertise beyond a singular focus and into a broader healthcare context. These varied interests underpin Novo Nordisk's ambition to provide a wide range of treatments for complex medical conditions.

Current Market Status

Today, Novo Nordisk continues to stand tall in the healthcare market, with a robust global presence that spans dozens of countries. Despite the challenges in the pharmaceutical industry, including competitive markets and regulatory pressures, the company has maintained a strong financial performance. Its commitment to innovation in diabetes care and beyond has ensured its position as a leader in the sector, making it a key player in today's global healthcare landscape.